

Application No. 09/277,229  
Amdt. Dated: September 16, 2005  
Supplemental Amendment

PATENT APPLICATION**REMARKS**

Claims 11-14 and 22-28 are pending in the subject patent application.

At the examiner's request, applicants respectfully direct the examiner's attention to the originally filed specification, which together with SEQ ID NO:4 provides support for the recitation in claim 11. Specifically, the polypeptide includes the transmembrane domain and identifies the transmembrane domain as spanning amino acids 461-477. (Specification, page 93, lines 12-13). All of the polypeptides recited in claim 11 include these amino acids of the transmembrane domain.


Claim 14 has been amended at the examiner's suggestion to recite "[a]n isolated biologically active polypeptide", support for which may be found in the originally filed specification *inter alia* at page 93, lines 17-18. No new matter has been added by this amendment.

During applicants' December 7, 2005 telephone with the examiner, it was discovered that a discrepancy exists between the U.S. PTO copy of the originally filed specification and applicants' copy of the originally filed specification. Specifically, the U.S. PTO copy differs by two pages, *i.e.*, is shorter by two pages, than applicants' copy. Therefore, in the U.S. PTO copy of the specification, page 91 corresponds to applicants' page 93. Applicants will order a copy of the originally filed specification from the U.S. PTO to ascertain how these discrepancies occurred.

**CONCLUSION**

In view of the foregoing, it is believed that the subject application is in condition for allowance, a notice of which is earnestly solicited by applicants.

Respectfully submitted,



Date: December 7, 2005

Estelle J. Tseydos  
Attorney for Applicants  
Registration No.: 31,145  
Phone: (212) 309-1021  
Fax: (212) 309-1100

Please send all future correspondence to:

Hunton & Williams LLP  
200 Park Avenue, 52<sup>nd</sup> Floor  
New York, New York 10166-0005